Amaral and collaborators (2020) investigated the effect of Psd1 on tumor cell viability, and the results showed a significant inhibition of viability in a dose-dependent manner after a treatment of 24 h, with a 50 to 60% reduction in the cells when treated with 25 and 50 μM of the peptide [76]. The gene discussed is PSD; the disease is neoplasm.